Table 2.
Selected trials of isatuximab in multiple myeloma
| Clinical Trial | Phase | Setting | Treatment | ORR (%) | CR (%) | MRD neg (%) |
|---|---|---|---|---|---|---|
| *First -in human isatuxiamb | 1 | RRMM | Monotherapy, dose-escalation | 18,2 (1–5 mg/kg) 23,8 (≥10 mg/kg) |
0 1,6 |
NA |
|
NCT 02283775 (PomdeSAR) |
1 B | RRMM | Isa-Pd | 62,2 | 4,4 | NA |
| NCT 02332850 | 1 B | RRMM | Isa-Kd | 66 | 3,4 | NA |
| NCT 01749969 | 1 B | RRMM | Isa-Rd | 56 | 3,8 | NA |
|
NCT 02990338 (ICARIA—MM) |
3 | RRMM | Isa-Pd vs Pd | 60 vs 35 | 5 vs 2 | 5 vs 0 |
|
NCT 03275285 (IKEMA) |
3 | RRMM | Isa-Kd vs Kd | 87 vs 83 | 40 vs 28 | 30 vs 13 |